Ligand Pharmaceuticals (LGND) Non-Current Deferred Tax Liability (2010 - 2026)

Ligand Pharmaceuticals (LGND) has 14 years of Non-Current Deferred Tax Liability data on file, last reported at $22.6 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Deferred Tax Liability fell 23.03% year-over-year to $22.6 million; the trailing twelve-month figure through Mar 2026 stood at $22.6 million (down 23.03% YoY), and the FY2025 full-year result was $36.0 million, down 50.75% from the prior year.
• Non-Current Deferred Tax Liability declined to $22.6 million in Q1 2026, from $36.0 million in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $73.1 million in Q4 2024 to a low of $22.6 million in Q1 2026.
• A 5-year average of $35.7 million and a median of $31.6 million in 2023 frame the typical range for Non-Current Deferred Tax Liability.
• Across the five-year window, Non-Current Deferred Tax Liability sank 57.66% in 2022 and jumped 131.3% in 2024, its largest moves.
• Tracing LGND's Non-Current Deferred Tax Liability over 5 years: stood at $30.6 million in 2022, then grew by 3.29% to $31.6 million in 2023, then jumped by 131.3% to $73.1 million in 2024, then plunged by 50.75% to $36.0 million in 2025, then sank by 37.22% to $22.6 million in 2026.
• Business Quant data shows LGND's Non-Current Deferred Tax Liability at $22.6 million in Q1 2026, $36.0 million in Q4 2025, and $22.7 million in Q3 2025.